It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
HOLX’s FA Score shows that 0 FA rating(s) are green whileSRTS’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
HOLX’s TA Score shows that 5 TA indicator(s) are bullish while SRTS’s TA Score has 4 bullish TA indicator(s).
HOLX (@Pharmaceuticals: Other) experienced а -0.37% price change this week, while SRTS (@Medical/Nursing Services) price change was -3.32% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.19%. For the same industry, the average monthly price growth was -0.65%, and the average quarterly price growth was +3.82%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +7.68%. For the same industry, the average monthly price growth was +8.00%, and the average quarterly price growth was +7.22%.
HOLX is expected to report earnings on Nov 03, 2025.
SRTS is expected to report earnings on Nov 06, 2025.
Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical/Nursing Services (+7.68% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
HOLX | SRTS | HOLX / SRTS | |
Capitalization | 15.1B | 55.1M | 27,405% |
EBITDA | 1.09B | 3.02M | 36,174% |
Gain YTD | -5.937 | -51.590 | 12% |
P/E Ratio | 28.14 | 31.50 | 89% |
Revenue | 4.04B | 39.5M | 10,225% |
Total Cash | 1.88B | 19.1M | 9,838% |
Total Debt | 2.52B | 654K | 385,780% |
HOLX | SRTS | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 80 Overvalued | 66 Overvalued | |
PROFIT vs RISK RATING 1..100 | 83 | 95 | |
SMR RATING 1..100 | 66 | 87 | |
PRICE GROWTH RATING 1..100 | 49 | 91 | |
P/E GROWTH RATING 1..100 | 47 | 17 | |
SEASONALITY SCORE 1..100 | 65 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SRTS's Valuation (66) in the Medical Specialties industry is in the same range as HOLX (80). This means that SRTS’s stock grew similarly to HOLX’s over the last 12 months.
HOLX's Profit vs Risk Rating (83) in the Medical Specialties industry is in the same range as SRTS (95). This means that HOLX’s stock grew similarly to SRTS’s over the last 12 months.
HOLX's SMR Rating (66) in the Medical Specialties industry is in the same range as SRTS (87). This means that HOLX’s stock grew similarly to SRTS’s over the last 12 months.
HOLX's Price Growth Rating (49) in the Medical Specialties industry is somewhat better than the same rating for SRTS (91). This means that HOLX’s stock grew somewhat faster than SRTS’s over the last 12 months.
SRTS's P/E Growth Rating (17) in the Medical Specialties industry is in the same range as HOLX (47). This means that SRTS’s stock grew similarly to HOLX’s over the last 12 months.
HOLX | SRTS | |
---|---|---|
RSI ODDS (%) | N/A | 4 days ago83% |
Stochastic ODDS (%) | 4 days ago52% | 4 days ago89% |
Momentum ODDS (%) | 4 days ago57% | 4 days ago84% |
MACD ODDS (%) | 4 days ago56% | 4 days ago77% |
TrendWeek ODDS (%) | 4 days ago58% | 4 days ago84% |
TrendMonth ODDS (%) | 4 days ago57% | 4 days ago81% |
Advances ODDS (%) | 11 days ago51% | 5 days ago85% |
Declines ODDS (%) | 4 days ago53% | 8 days ago83% |
BollingerBands ODDS (%) | 5 days ago53% | 4 days ago86% |
Aroon ODDS (%) | 4 days ago52% | 4 days ago80% |
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
CCIF | 5.71 | 0.03 | +0.62% |
Carlyle Credit Income Fund | |||
WCME | 16.16 | 0.07 | +0.40% |
First Trust WCM Devpg Wld Eq ETF | |||
FELV | 32.50 | -0.05 | -0.15% |
Fidelity Enhanced Large Cap Value ETF | |||
EPV | 25.28 | -0.06 | -0.24% |
ProShares UltraShort FTSE Europe | |||
AIVL | 113.12 | -0.43 | -0.38% |
WisdomTree US Al Enhanced Val ETF |
A.I.dvisor indicates that over the last year, HOLX has been loosely correlated with ZBH. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if HOLX jumps, then ZBH could also see price increases.
Ticker / NAME | Correlation To HOLX | 1D Price Change % | ||
---|---|---|---|---|
HOLX | 100% | -0.37% | ||
ZBH - HOLX | 43% Loosely correlated | +0.62% | ||
RVTY - HOLX | 40% Loosely correlated | +1.49% | ||
QGEN - HOLX | 40% Loosely correlated | +0.80% | ||
BDX - HOLX | 40% Loosely correlated | +0.48% | ||
WAT - HOLX | 39% Loosely correlated | -0.67% | ||
More |
A.I.dvisor tells us that SRTS and HOLX have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SRTS and HOLX's prices will move in lockstep.
Ticker / NAME | Correlation To SRTS | 1D Price Change % | ||
---|---|---|---|---|
SRTS | 100% | -2.62% | ||
HOLX - SRTS | 27% Poorly correlated | -0.37% | ||
MYO - SRTS | 27% Poorly correlated | -0.51% | ||
MTD - SRTS | 26% Poorly correlated | -0.10% | ||
PLSE - SRTS | 26% Poorly correlated | -6.64% | ||
BFLY - SRTS | 26% Poorly correlated | N/A | ||
More |